$2.21
0.45%
Nasdaq, Sep 18, 04:00 pm EDT. Closed.
ISIN
US53630X1046
Symbol
LPCN

Lipocine, Inc. Stock price

$2.21
+0.17 8.33% 1M
-5.09 69.73% 6M
-5.82 72.48% YTD
-0.60 21.35% 1Y
-1.24 35.94% 3Y
-16.66 88.29% 5Y
-56.44 96.23% 10Y
-847.79 99.74% 20Y
Nasdaq, Closing price Fri, Sep 18 2026
-0.01 0.45%
ISIN
US53630X1046
Symbol
LPCN
Industry

Is Lipocine, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,133 stocks worldwide.

Key metrics

Basic
Market capitalization
$18.2m
Enterprise Value
$-5.1m
Net debt
positive
Cash
$23.3m
Shares outstanding
8.2m
Valuation (TTM | estimate)
P/E
negative
P/S
11.6 | 31.0
EV/Sales
negative | negative
EV/FCF
0.5
P/B
0.8
Financial Health
Equity Ratio
85.1%
Return on Equity
-66.5%
ROCE
-57.7%
ROIC
2,923.0%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$1.6m | $588.0k
EBITDA
$-12.5m
EBIT
$-12.6m
Net Income
$-11.9m
Free Cash Flow
$-11.2m
Growth (TTM | estimate)
Revenue
-62.7% | -70.3%
EBITDA
-126.2%
EBIT
-125.3%
Net Income
-162.7%
Free Cash Flow
-124.3%
Margin
Gross
-
EBITDA
-797.1%
EBIT
-800.8%
Net
-755.1%
Free Cash Flow
-713.0%
More
EPS
$-1.4
FCF per Share
$-1.4
Short interest
1.3%
Employees
14
Rev per Employee
$140.0k

Lipocine, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Lipocine, Inc. forecast:

6x Buy
75%
2x Hold
25%

Analyst Opinions

8 Analysts have issued a Lipocine, Inc. forecast:

Buy
75%
Hold
25%

Financial data from Lipocine, Inc.

Jun '26
+/-
%
1.57 1.57
63% 63%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 3.95 3.95
0% 0%
252%
- Research and Development Expense 10 10
74% 74%
649%
-13 -13
126% 126%
-797%
- Depreciation and Amortization 0.06 0.06
20% 20%
4%
EBIT (Operating Income) EBIT -13 -13
125% 125%
-801%
Net Profit -12 -12
163% 163%
-755%

In millions USD.

Don't miss a Thing! We will send you all news about Lipocine, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Lipocine, Inc. Stock News

Neutral
PRNewsWire
7 days ago
Study informed by encouraging exploratory efficacy findings and a favorable safety profile in the prior Phase 3 trial Approximately 120 participants with severe postpartum depression (PPD) planned; first participant dosing expected in early Q4 2026 Company expects existing resources to support BLOOM SALT LAKE CITY, Sept. 14, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a specialty pharmac...
Neutral
PRNewsWire
about 2 months ago
SALT LAKE CITY, Aug. 4, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company focused on the development of novel oral therapeutics, today announced financial results for the second quarter ended June 30, 2026 and provided a corporate update. Recent Developments and Corporate Update LPCN 1154 (BRLIZIO™) for Postpartum Depression (PPD) On April 2, 2026, Lipocine r...
Neutral
PRNewsWire
about 2 months ago
SALT LAKE CITY, Aug. 3, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced the appointment of Michael J. Grissinger to its Board of Directors, effective August 3, 2026.
More Lipocine, Inc. News

Company Profile

Lipocine, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development for the delivery of drugs using proprietary delivery technology. The firm involves in applying oral drug delivery technology for the development of pharmaceutical products focusing on metabolic and endocrine disorders. It offers TLANDO, an oral testosterone replacement therapy. The company was founded in 2011 and is headquartered in Salt Lake City, UT.

Head office United States
CEO Dr. Patel
Employees 14
Founded 2011
Website www.lipocine.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today